Analyst consensus rating
NewAmsterdam Pharma Analyst Rating: Strong Buy
Direct answer
NewAmsterdam Pharma's consensus rating is Strong Buy.
15 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $51.65.
Forecast evidence checked September 7, 2026.
Get free NewAmsterdam Pharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $25.40
- Average price target
- $51.65
- High price target
- $60.41
- Low price target
- $38.26
- Low target gap
- +50.6%
- Target upside
- +103.4%
- High target gap
- +137.8%
- Target range width
- 87.2%
- Consensus rating
- Strong Buy
- Analysts
- 15
- Evidence date
- September 7, 2026
- Valid through
- September 14, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for NewAmsterdam Pharma?
NewAmsterdam Pharma has a verified Strong Buy consensus. The same dataset has an average price target of $51.65.
How far are NewAmsterdam Pharma's low and high targets from the recorded price?
The low target implies +50.6%, while the high target implies +137.8%.
How many analysts are included in NewAmsterdam Pharma's consensus?
The verified consensus includes 15 analysts.
How is NewAmsterdam Pharma's target upside or downside calculated?
The average target of $51.65 is divided by the recorded price of $25.40, then one is subtracted to produce +103.4%. This does not guarantee a future return.
When was NewAmsterdam Pharma's analyst forecast verified?
The data was verified on 2026-09-07. The dataset is valid through 2026-09-14.